期刊文献+

Optimal control homotopy perturbation method for cancer model 被引量:1

原文传递
导出
摘要 In this paper, we introduced the optimal control homotopy perturbation method (OCHPM) by using the homotopy perturbation method (HPM). Every one, by using of the proposed method, can obtain numerical solutions of mathematical modeling for cancer-immunotherapy. In this paper, in order to prove the preciseness and efficiency of the OCHPM method, we compared the obtained numerical solutions with HPM. The results obtained showed that the OCHPM method is powerful to generate the numerical solutions for some therapeutic models.
出处 《International Journal of Biomathematics》 SCIE 2019年第3期79-90,共12页 生物数学学报(英文版)
  • 相关文献

参考文献1

二级参考文献12

  • 1Ferlay J,Shin HR,Bray F,Forman D Mathers C Parkin DM. Estimates of worldwide burden of cancer in,2008:GLOBOCAN,2008[J].International Journal of Cancer,2010.2893-2917.
  • 2Bray F,Jemal A,Grey N,Ferlay J Forman D. Global cancer transitions according to the Human Development Index(2008-2030):a population-based study[J].Lancet Oncology,2012.790-801.
  • 3Hanahan D,Weinberg AR. hTe hallmarks of cancer[J].Cell,2000.57-70.
  • 4Hanahan D,Weinberg AR. Hallmarks of cancer:the next generation[J].Cell,2011.646-674.
  • 5Vogelstein B,Papadopoulos N,Velculescu VE,Zhou S Diaz LA Kinzler KW. Cancer genome landscapes[J].Science,2013.1546-1558.
  • 6Garraway LA,Lander ES. Lessons from the cancer genome[J].Cell,2013.17-37.
  • 7Socinski MA,Bondarenko I,Karaseva NA,Makhson AM Vynnychenko I Okamoto I. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as ifrst-line therapy in patients with advanced non-small-cell lung cancer:ifnal results of a phase III trial[J].Journal of Clinical Oncology,2012.2055-2062.
  • 8Von Hoff DD,Ervin TJ,Arena FP,Chiorean EG, Infante JR, Moore MJ,. Results of a randomized phase III trial(MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates[J].Journal of Clinical Oncology,2013.4005.
  • 9Tan J,Cang S,Ma Y,Petrillo RL Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents[J].J Hematol Oncol,2010.5.
  • 10Juergens AR,Wrangle J,Vendetti FP,Murphy SC Zhao M Coleman B. Combination epigenetic therapy has effcacy in patients with refractory advanced non-small cell lung cancer[J].Cancer Discov,2011.598-607.

共引文献1

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部